CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions

CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.

Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer

Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for approximately 70% of breast cancer cases. Despite recent advances with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), resistance inevitably develops, often driven by activation of the phosphatidylinositol 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway. Genetic alterations such as PIK3CA mutations (present in ~ 45% of HR+/HER2- tumors), AKT1 mutations, and PTEN loss contribute to endocrine resistance and poor outcomes. This review summarizes emerging strategies targeting this pathway to overcome resistance in advanced disease. Isoform-specific PI3K inhibitors, including alpelisib and inavolisib, have demonstrated clinically meaningful progression-free survival benefits in PIK3CA-mutated populations, with inavolisib showing improved tolerability and efficacy. In contrast, pan-PI3K inhibitors such as buparlisib have been constrained by toxicity. Targeting downstream signaling, AKT inhibitors have also shown benefit: capivasertib has demonstrated clinical efficacy leading to US Food and Drug Administration approval, while ipatasertib has yielded encouraging results, particularly in tumors harboring PIK3CA, AKT1, or PTEN alterations. Mammalian target of rapamycin inhibitors, notably everolimus, have shown efficacy irrespective of mutation status. The dual PI3K-mTOR inhibitor (gedatolisib) has also shown promising progression-free survival benefit in a PIK3CA wild-type population. Next-generation agents, including mutant-selective PI3Kα inhibitors and bi-steric mTOR complex 1 inhibitors, are under active investigation. Optimal sequencing of these agents alongside endocrine therapy and CDK4/6i options remain a critical question, as does integration of genomic testing to guide therapy. Future directions include rational combination strategies, improved biomarker-driven selection, and novel modalities such as proteolysis-targeting chimeras (PROTACs). Collectively, these advances aim to enhance durability of response, minimize toxicity, and improve survival in HR+/HER2- metastatic breast cancer.

Molecular targeting of CDK9 in oncology therapeutics: avenues for translational impact.

BACKGROUND Cyclin-dependent kinase 9 (CDK9) is a central regulator of RNA polymerase II elongation and has emerged as a therapeutic target in tumors characterized by transcriptional addiction. Growing interest in selective inhibitors and targeted degraders has renewed attention to the translational potential of CDK9-directed therapy. AREAS COVERED This review summarizes the molecular functions of the CDK9/positive transcription elongation factor b (P-TEFb) axis, its role in super-enhancer-driven oncogenic programs, and the mechanisms by which CDK9 inhibition promotes apoptosis, epigenetic derepression, and tumor microenvironment remodeling. We also discuss representative small-molecule inhibitors and proteolysis-targeting chimera (PROTAC) degraders, emerging biomarkers for patient stratification, rational combination strategies, and the current landscape of resistance mechanisms. EXPERT OPINION Selective targeting of CDK9 offers a promising route for treating refractory malignancies, particularly when guided by transcriptional dependency, biomarker-informed dosing, and rational combination design. Future progress will likely depend on improving therapeutic index, refining translational biomarkers, and anticipating adaptive resistance during clinical development.

CDK4/6-Based Drug Research and Development: A Four-Year Update.

INTRODUCTION CDK4/6 kinases are crucial cell cycle regulators, and pharmacological inhibition of these kinases to block the G1-to-S phase transition has become an integral part of modern cancer therapy. Although five CDK4/6 inhibitors have been clinically approved, the development of acquired drug resistance greatly limits their long-term therapeutic efficacy. METHODS This review systematically summarizes the latest advances in CDK4/6 inhibitor research from 2022 to 2025, focusing on their structural features, biological functions, and preclinical research progress. In addition, this article comprehensively explores emerging therapeutic strategies, including bifunctional molecules and PROTAC-based protein degraders. RESULTS The action mechanisms of conventional CDK4/6 inhibitors have been relatively well elucidated. Notably, these emerging strategies have yielded encouraging preclinical results, including co-targeting CDK4/6 with other critical therapeutic nodes (e.g., HDAC, PARP1) and adopting PROTAC-based degraders to directly induce the degradation of target proteins. A growing number of innovative approaches targeting drug resistance via multi-target inhibition and induced protein degradation have been developed. Distinct from classical singletarget monotherapy, these innovative strategies leverage distinct pharmacological pathways, offering feasible research directions to improve therapeutic efficacy and delay drug resistance. DISCUSSION In-depth understanding of CDK4/6 inhibitors and the continuous development of bifunctional agents and protein degraders provides key theoretical and technical support for the design of next-generation therapeutic strategies to address current clinical limitations. These research advances are expected to facilitate the development of more effective and long-lasting therapeutic modalities for tumor treatment. CONCLUSION This review summarizes recent advances in CDK4/6 inhibitors. Novel dual-target and PROTACbased strategies offer promising resistance-overcoming tumor therapies.

Breast Cancer CDK4/6 Inhibitor Resistance and Immunotherapy Strategies

Breast cancer remains the most common cancer among women worldwide. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have emerged as key targeted therapies. They primarily prevent tumor growth in hormone receptor-positive breast cancer by blocking the cell cycle. These drugs not only directly slow down cell growth but also significantly alter the tumor immune microenvironment in important ways. They enhance antigen presentation, facilitate T-cell infiltration into tumors, and reduce the activity of regulatory T cells that suppress immune responses. In clinical practice, drug resistance remains a major issue. This resistance may be present from the outset or develop over time, greatly limiting the long-term efficacy of these drugs. This article reviews the two main ways in which CDK4/6 inhibitors exert their effects. One is to directly block the cell cycle, and the other is to reshape the immune microenvironment. The article also discusses various reasons for drug resistance and explores solutions to this problem. Combination therapy is one option. Its purpose is to provide theoretical support for improving this targeted treatment approach. However, there is still a major issue. The existing CDK4/6 inhibitors are not effective for all subtypes. They have poor efficacy in triple-negative breast cancer. This subtype has the highest mortality rate, grows rapidly, and lacks targeted treatment options. Research is needed to expand the use of these drugs. The research should focus on the forms of resistance and also on under-served subtypes such as triple-negative breast cancer. This work is urgent and will help improve the treatment outcomes for all breast cancer patients.

Precision oncology in breast cancer: Biomarker-driven treatment strategies and the expanding role of APPs.

ABSTRACT Recent advances in breast cancer management have transformed treatment across molecular subtypes and expanded the role of precision oncology. Hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-positive (HER2-positive), HER2-low, and triple-negative breast cancer (TNBC) each demonstrate distinct biologic behavior requiring tailored therapeutic strategies. In HR-positive disease, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and next-generation selective estrogen receptor degraders have improved survival, while HER2-directed antibody-drug conjugates (ADCs) have expanded treatment options beyond traditional HER2-positive disease. HER2-low disease has recently emerged as a therapeutically actionable HER2-expression category, addressing a previously limited treatment space. In TNBC, immunotherapy and ADCs have broadened therapeutic options for historically difficult-to-treat disease. Advances in genomic profiling, including next-generation sequencing and circulating tumor DNA testing, allow clinicians to identify biomarkers to guide targeted therapy selection. As treatment complexity increases, APPs play an essential role in implementing precision oncology through patient education, toxicity management, genomic counseling, and clinical trial coordination. This review summarizes current treatment strategies across breast cancer subtypes, highlights emerging therapies, and emphasizes the expanding APP role.